Swixx BioPharma secures close to €100 million to fuel its growth

▤ Summary

The strong Swiss pharma and biotech cluster includes not only drug development companies but also service providers. Mérieux Equity Partners (MxEP) will invest €40 million into Swixx, taking a minority position. HBM’s and MxEP’s investments should close during the next few months, depending upon completion of routine regulatory approvals. MxEP has arrangements in place to increase its investment in Swixx up to €90 million, based upon the realisation of certain milestones. “It is my great pleasure to announce this agreement with our three banking partners”, commented Swixx CFO Petr Pipal.

▦ Linked Companies